Combination of Conservative and Interventional Therapy Strategies for Intra- and Extrahepatic Cholangiocellular Carcinoma: A Retrospective Survival Analysis

Table 1

Age, localisation, therapies, and results of all patients with diagnosis of cholangiocarcinoma.

Variables	Total	(𝑛)	Women	(𝑛)	Men	(𝑛)
		(𝑛=195)		(𝑛=84)		(𝑛=111)
Median age at point of diagnosis	58.47 (±12.28)		56.83 (±10.74)		59.70 (±13.24)
Median age at point of death	59.62 (±11.97)		58.12 (±11.03)		60.71 (±12.57)
Localisation
C22.1	111 (56.9%)		48 (57.1%)		63 (56.8%)
C24.0	84 (43.1%)		36 (42.9%)		48 (43.2%)
Therapy
OP	63 (34.1%)	(𝑛=185)	28 (35.4%)	(𝑛=79)	35 (33.0%)	(𝑛=106)
adjuvant chemotherapy	15 (8.2%)	(𝑛=183)	7 (9.0%)	(𝑛=78)	8 (7.6%)	(𝑛=105)
photodynamic therapy	14 (7.7%)	(𝑛=183)	6 (7.6%)	(𝑛=79)	8 (7.7%)	(𝑛=104)
TACE	18 (9.8%)	(𝑛=183)	12 (15.2%)	(𝑛=79)	6 (5.8%)	(𝑛=104)
chemotherapy	137 (80.6%)	(𝑛=170)	60 (83.3%)	(𝑛=72)	77 (78.6%)	(𝑛=98)
Results of therapy		(𝑛=184)		(𝑛=81)		(𝑛=103)
no tumor	11 (6.0%)		7 (8.6%)		4 (3.9%)
complete remission	6 (3.3%)		4 (4.9%)		2 (1.9%)
partial remission	4 (2.2%)		1 (1.2%)		3 (2.9%)
Reduction of tumor mass without def. Rem.	6 (3.3%)		1 (1.2%)		5 (4.9%)
unchanged	8 (4.3%)		2 (2.5%)		6 (5.8%)
progress	140 (76.1%)		62 (76.5%)		78 (75.7%)
no result of primary therapy	9 (4.9%)		4 (4.9%)		5 (4.9%)
Survival after		(𝑛=195)		(𝑛=84)		(𝑛=111)
3 months	165 (84.6%)		74 (88.1%)		91 (82.0%)
6 months	140 (71.8%)		65 (77.4%)		75 (67.6%)
12 months	99 (50.8%)		47 (56.0%)		52 (46.8%)
Event of death	154 (80.6%)	(𝑛=191)	65 (80.2%)	(𝑛=81)	89 (80.9%)	(𝑛=110)